PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Cancer Res. Author manuscript; available in PMC Aug 1, 2011.
Published in final edited form as:
PMCID: PMC2912953
NIHMSID: NIHMS215756
TGF-β-Inducible Gene TMEPAI Converts TGF-β from a Tumor Suppressor to a Tumor Promoter in Breast Cancer
Prajjal K. Singha, I-Tien Yeh, Manjeri A. Venkatachalam, and Pothana Saikumar*
Department of Pathology, UT Health Science Center at San Antonio, TX
* Corresponding Author: Pothana Saikumar PhD, Department of Pathology, UT Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229; 210-567-6597; saikumar/at/uthscsa.edu
TMEPAI is a TGF-β-induced transmembrane protein that is overexpressed in several cancers. How TMEPAI expression relates to malignancy is unknown. Here we report high expression of TMEPAI in ER/PR-negative and HER2-negative breast cancer cell lines and primary breast cancers that was further increased by TGF-β treatment. Basal and TGF-β-induced expression of TMEPAI was inhibited by the TGF-β receptor antagonist SB431542 and overexpression of Smad7 or a dominant negative mutant of Alk-5. TMEPAI knockdown attenuated TGF-β-induced growth and motility in breast cancer cells, suggesting a role for TMEPAI in growth promotion and invasiveness. Further, TMEPAI knockdown decreased breast tumor mass in a mouse xenograft model in a manner associated with increased expression of PTEN and diminished phosphorylation of Akt. Consistent with effects via the PI3K pathway, tumors with TMEPAI knockdown exhibited elevated levels of the cell cycle inhibitor p27kip1 and attenuated levels of DNA replication and expression of HIF-1α and VEGF. Together, these results suggest that TMEPAI functions in breast cancer as a molecular switch that converts TGF-β from a tumor suppressive to a tumor promoting role.
Both single-copy gains and high level regional amplification of chromosomal arm 20q (~ 5- to 10-fold) occur in human breast cancer (1, 2) and other tumors (2). This suggests a role for genes on 20q in tumor pathogenesis. 20q amplification is associated with immortalization and avoidance of cell senescence (3). TGF-β overactivity induces replicative senescence in untransformed cells and in oncogene transduced primary epithelial cultures (4) but is paradoxically oncogenic in established cancer, including breast cancer (5, 6). Genes involved in bypassing senescence checkpoints could be the “missing links” that connect TGF-β to oncogenesis. TMEPAI, a TGF-β inducible gene (7) mapped to 20q13.3 (8), encodes a NEDD4 E3 ubiquitin ligase binding protein (9) and is overexpressed in cancers (7, 1013) including breast cancer (10, 13). We speculated whether TMEPAI plays a role in breast cancer by favoring growth and invasion and/or antagonizing the tumor suppressive functions of TGF-β. We investigated the consequences of TMEPAI expression and knockdown using in vitro culture models and in vivo murine xenografts. TMEPAI profoundly affected the growth, motility and invasiveness of cultured breast cancer cells, growth of tumor xenografts, and expression of PTEN, p27kip1, Hif-1α and VEGF. In view of our data showing TMEPAI gene amplification in breast cancer (13), we suggest that overexpression and/or increased or altered function of TMEPAI may be a “molecular switch” that converts TGF-β from tumor suppressor to tumor promoter. A recent report that TMEPAI sequesters Smad proteins to decrease TGF-β signaling (14) and our unpublished data are consistent with this premise. However, our findings suggest that the effects of TMEPAI may be even more pervasive and critically relevant to cancer progression than its Smad sequestering function would suggest.
Cell culture and Cell proliferation
All previously authenticated breast cell lines obtained from ATCC before 2009 were used. All of them tested positive for human origin and absence or presence of estrogen receptor α and HER2. Breast cancer cells [MDA-MB-231, BT-20, and MDA-MB-468(DMEM); HCC-1937 and T-47D (RPMI); CAMA-1 and MCF-7 (Minimal Essential Medium)] were grown in their respective medium with 10% fetal bovine serum. hTERT-HME1 cells were grown in Mammary Epithelial Basal Medium with required additives. All cells were maintained at 37°C in 5% CO2. MDA-MB-231 cells, after receipt, were grown initially in L-15 medium without CO2 and later shifted to DMEM. Cell proliferation was measured by either counting cells in a haemocytometer or quantitation of total cell DNA by Hoechst 33258. Since all isoforms of TGF-β behaved similarly in TMEPAI induction, all experiments described here were carried out with TGF-β1 at 2ng/ml concentration.
Quantitative real-time-PCR
Total RNA was used for qPCR with TMEPAI specific primers and SYBR green PCR master mix in an Applied Biosystems 7500 Real-Time PCR System. The nucleotide sequences for PCR primers were: TMEPAI:5′-GCACAGTGTCAGGCAACGG -3′(forward)and 5′-AGATGGTGGGTGGCAGGTC-3′ (reverse); 18S rRNA:5′-GAGAAACGGCTACCACATCC-3′ (forward) and 5′-CACCAGACTTGCCCTCCA-3′ (reverse).
TMEPAI knockdown and Immunoblotting
pLKO.1-based lentiviral vectors were packaged in 293T cells. shRNAs of human TMEPAI (shRNA1:5′-GAGCAAAGAGAAGGATAAACA-3′ and shRNA2:5′-GTCCCTATGAATTGTACGTTT-3′) cloned in lentiviral vectors were from Open Biosystems. MDA-MB-231 cells were infected with viral supernatants for 24 h at 37°C with 8 μg/ml Polybrene (Sigma) and selected with puromycin to obtain stable lines with TMEPAI knockdown. Total cell-lysates were immunoblotted as described(15).
Tumorigenesis and Migration Assays
MDA-MB-231 cells (2 × 106) expressing control or TMEPAI shRNA were implanted subcutaneously in 5- to 6-week-old female nude mice (6 animals/each group). Tumor volumes were measured with a caliper weekly. After 6 weeks, mice were sacrificed. Tumors were removed and processed for immunoblotting and immunohistochemistry (IHC). Migration and invasion assay was performed using Transwell Matrigel Invasion chamber (16) and wound induced migration as described (17, 18).
TMEPAI gene amplification and expression in invasive breast ductal cancers and TGF-β regulation of TMEPAI expression
We reported in abstract form that TMEPAI gene is commonly amplified in breast cancers, particularly in ductal carcinomas, including a majority of triple negative tumors (13). We used array comparative genomic hybridization (aCGH) to detect genomic imbalances in cancers from 97 patients. While 45/85(53%) invasive ductal carcinomas and 2/11 (18%) invasive lobular carcinomas showed gain (26/97, 26.8%) or high copy gain (21/97, 21.6%) of TMEPAI, 18 of 31(58.1%) triple negative cancers showed gene amplification. Most tumors with gene amplification were grade 3 tumors (34/47, 72.3%) (13). While these studies are being prepared for publication in article form, we felt that TMEPAI amplification may be a factor that increases cancer aggressiveness. In silico analysis of the Oncomine data base using published methods(19)suggested that TMEPAI expression is higher (P < 0.001) in invasive breast cancer compared to normal breast (supplement Fig. S1). Given TMEPAI amplification in 58.1% of triple negative breast cancers, we tested for TMEPAI protein expression in 4 triple negative breast cancers and corresponding normal/benign tissues by western blotting. Each of four matched normal/benign tissues did not express TMEPAI, whereas all four cancers exhibited varied levels of expression(Fig. 1A).
Figure 1
Figure 1
TMEPAI expression in invasive breast ductal cancers and its regulation by TGF-β signaling
TMEPAI expression was assessed in 7 breast cancer cell lines. Three of four triple negative or phenotypically basal-like lines expressed more TMEPAI protein (MDA-MB-231, BT-20, HCC1937) than three estrogen receptor (ER) positive non invasive lines (MCF-7, T47D and CAMA-1) (Fig. 1B). MDA-MB-231 cells are devoid of ER and HER2 receptors and highly sensitive to TGF-β (20). Treatment of MDA-MB-231 cells with TGF-β for 6h resulted in ~ 40-fold induction of TMEPAI mRNA (Fig. 1C, top panel)and ~9 fold increase of protein (Fig. 1C, bottom panel). Induction was blocked by SB431542, a TGF-β receptor I (Alk5) kinase inhibitor (Fig. 1C). Induction by TGF-β was minimal or nil for TMEPAI mRNA (Fig. 1C, top panel) or protein (supplement Fig. S2) in benign human mammary epithelial cells immortalized with telomerase (hTERT-HME1). Smad7 and dominant negative TGF-β receptor I (DN Alk5) blocked basal as well as TGF-β induced TMEPAI suggesting a requirement for TGF-β receptor and Smad dependent TGF-β signaling for induction (Fig. 1D, top panel). MCF-7 cells do not express or induce TMEPAI in response to TGF-β; however, they did respond when Alk5 was overexpressed (Fig. 1D, bottom panel) suggesting defective TGF-β receptor I in these cells. Thus, induction of TMEPAI may be a key hallmark of invasive breast cancer cells with intact TGF-β signaling.
Effects of TMEPAI knockdown on TGF-β dependent growth and migration
We used lentiviruses expressing 2 different TMEPAI shRNAs to assess their effects on growth, motility and invasive behavior of MDA-MB-231 cells. Both shRNAs ablated TMEPAI protein expression (Fig. 2A). TMEPAI was not expressed even in the presence of TGF-β. TMEPAI knockdown by either shRNA resulted in decreased cell growth, measured as increase of total DNA (Fig. 2B), or as cell number (not shown). Although TGF-β caused early growth inhibition of wild type and control shRNA expressing cells, there was a remarkable growth spurt after 72 hours of treatment; consequently, TGF-β treated cells outnumbered those without the cytokine by 96 hours (Fig. 2B). This effect was also observed in complete absence of serum (not shown). Importantly, TMEPAI shRNA inhibited proliferation regardless of exposure to TGF-β, at all time points (Fig. 2B). TMEPAI knockdown altered the morphological phenotype of MDA-MB-231 cells. By 72–96 hours of growth, cells with control shRNA displayed elongated and spindly morphology; without TGF-β, occasional cells showed loss of contact inhibition and growth of cells one on top of the other; with TGF-β, loss of contact inhibition was pronounced (supplement Fig. S3). In contrast, cells with TMEPAI shRNA displayed a cobblestone type epithelial morphology regardless of TGF-β treatment (supplement Fig. S3). We found a time-dependent increase of TMEPAI in TGF-β treated MDA-MB-231 cells that correlated with proliferation induced by the cytokine, including the late growth spurt (Fig. 2C). These data suggest that a critical concentration of TMEPAI may need to accumulate before the TGF-β induced growth spurt occurs.
Figure 2
Figure 2
TMEPAI knockdown blocks TGF-β stimulated growth, migration and invasion
Transwell invasion assays revealed extensive migration of MDA-MB-231 cells expressing control shRNA across matrigel in presence of TGF-β (Fig. 2D). Migration across the membrane, and therefore, invasion through matrigel, was impaired in cells expressing TMEPAI shRNA regardless of TGF-β treatment (Fig. 2D). We reported that wound induced migration of epithelial monolayers is associated with increased autocrine TGF-β signaling (17, 18). Therefore, we tested whether TMEPAI responds to wounding of MDA-MB-231 confluent monolayers. Wounding caused increased TMEPAI transcript and protein that was blocked by TGF-β receptor inhibitor SB431542 (Fig. 3A and 3B). Moreover, SB431542 inhibited the migration of wounded MDA-MB-231 cells (Fig. 3C), an effect mimicked by TMEPAI shRNA but not control shRNA (Fig. 3D). Because TMEPAI knockdown increases TGF-β signaling (14); and our unpublished data), these results show that TMEPAI affects cancer cell motility downstream of Smads. Whether TMEPAI knockdown attenuates cancer cell growth by releasing sequestered Smads, i.e., by increasing TGF-β signaling, or, as seems likely, by other effects as well, needs investigation. As indicated before, TGF-β inhibited MDA-MB-231 cell proliferation early, but promoted growth later (Fig. 2B). We are currently investigating how TMEPAI relates to this duality of TGF-β action that mirrors its paradoxical promotion of aggressiveness in established cancers (5).
Figure 3
Figure 3
Wound induced TMEPAI expression and cell migration
Inhibition of TMEPAI expression decreases tumor xenograft growth
Tumor volumes of MDA-MB-231 xenografts from cells with TMEPAI shRNA were less compared to those with control shRNA after 28 days (Fig. 4A, p<0.05). In agreement, the weights of TMEPAI knockdown tumors were correspondingly less (supplement Fig. S4). Expression of proliferation marker Ki67 was decreased by >70% in TMEPAI shRNA tumors relative to shRNA controls (Fig. 4B; and supplement Fig. S5) without any significant increase in apoptotic index by TUNEL staining (not shown) and expression of angiogenic factor VEGF was dramatically reduced in xenografts expressing TMEPAI shRNA (Fig. 4B and 4C). Both cultures and tumors derived from TMEPAI knockdown cells expressed lower levels of Hif-1α protein (Fig. 4C). Furthermore, TMEPAI knockdown resulted in reduced Akt phosphorylation, an event that promotes growth, and this was associated with increased expression of growth suppressors PTEN and p27kip1 (Fig. 4D).
Figure 4
Figure 4
Inhibition of TMEPAI expression decreases human breast tumor growth in nude mice
Our results show that profound effects of TMEPAI knockdown on the biology of a triple negative breast cancer cell line are accompanied by important alterations of several gene products that control cancer progression. While we have not investigated how these diverse effects come about, we suggest that they are related to the potent actions of TMEPAI expression or knockdown. The multiplicity of effects on tumor promoters (HIF-1α, VEGF) and tumor suppressors (PTEN, TGF-β, p27kip1) congruently converging along a potentially beneficial direction is unusual for an intervention involving a single gene product. Therefore, we hypothesize that TMEPAI is a “master regulator’ of cancer progression. Our report provides detailed studies on only one cell line MDA-MB-231. Nevertheless, this cell line is a well studied and common model for aggressive breast cancers with demonstrated relevance in published work. While we are currently studying a more diverse variety of breast cancer cells, the ancillary data we provide offer support to our belief in the importance of TMEPAI and its relevance to cancer biology. Therefore these findings merit early attention by investigators in the field.
The supportive data include identification of the region amplified on 20q in breast cancers as the TMEPAI gene, provide evidence for local copy number variations and suggest that the majority of triple negative and invasive phenotypes are associated with copy gain (13). Furthermore, elevation of TMEPAI protein expression was observed not only in primary tumors but also in several breast cancer cell lines (Fig. 1). TMEPAI expression was detected mainly in invasive phenotypes of breast cancer cell lines.
Importantly, the data indicate that constitutive aberrant expression of TMEPAI not only promotes growth, migration, and invasion but also overcomes growth suppression by TGF-β. For these reasons it seems possible that molecular events affecting TMEPAI and/or associated proteins may constitute a “molecular switch” that converts TGF-β, normally a tumor suppressor, to a tumor promoter role in breast cancer.
Triple negative tumors remain a major cause of breast cancer mortality because of their invasiveness and metastatic potential and lack of suitable molecular targets for treatment. This first report of a role for TMEPAI in tumor growth and invasiveness and its relationship to TGF-β should spur interest in further investigation of its role in cancer cell signaling. Such studies could lead to the development of tumor biomarkers and treatment targets.
Supplementary Material
Acknowledgments
Financial assistance was provided by the Cancer Therapy and Research Center at the University of Texas Health Science Center San Antonio to P.S., through the NCI Cancer Center Support Grant, Grant number 2 P30 CA054174-17. We also acknowledge NIH grants DK54472 to P.S. and DK37139 to M.A.V. We thank Dr. Gabriel Fernandes of UTHSCSA for helping with the mice experiments.
1. Tanner MM, Tirkkonen M, Kallioniemi A, et al. Increased copy number at 20q13 in breast cancer: defining the critical region and exclusion of candidate genes. Cancer Res. 1994;54:4257–60. [PubMed]
2. Courjal F, Cuny M, Rodriguez C, et al. DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours. Br J Cancer. 1996;74:1984–9. [PMC free article] [PubMed]
3. Cuthill S, Agarwal P, Sarkar S, Savelieva E, Reznikoff CA. Dominant genetic alterations in immortalization: role for 20q gain. Genes Chromosomes Cancer. 1999;26:304–11. [PubMed]
4. Tremain R, Marko M, Kinnimulki V, Ueno H, Bottinger E, Glick A. Defects in TGF-beta signaling overcome senescence of mouse keratinocytes expressing v-Ha-ras. Oncogene. 2000;19:1698–709. [PubMed]
5. Padua D, Massague J. Roles of TGF-beta in metastasis. Cell Res. 2009;19:89–102. [PubMed]
6. Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev. 2006;25:435–57. [PubMed]
7. Brunschwig EB, Wilson K, Mack D, et al. PMEPA1, a transforming growth factor-beta-induced marker of terminal colonocyte differentiation whose expression is maintained in primary and metastatic colon cancer. Cancer Res. 2003;63:1568–75. [PubMed]
8. Xu LL, Shanmugam N, Segawa T, et al. A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate. Genomics. 2000;66:257–63. [PubMed]
9. Xu LL, Shi Y, Petrovics G, et al. PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression. Cancer Res. 2003;63:4299–304. [PubMed]
10. Giannini G, Ambrosini MI, Di Marcotullio L, et al. EGF-and cell-cycle-regulated STAG1/PMEPA1/ERG1.2 belongs to a conserved gene family and is overexpressed and amplified in breast and ovarian cancer. Mol Carcinog. 2003;38:188–200. [PubMed]
11. Hirokawa YS, Takagi A, Uchida K, et al. High level expression of STAG1/PMEPA1 in an androgen-independent prostate cancer PC3 subclone. Cell Mol Biol Lett. 2007 [PubMed]
12. Rae FK, Hooper JD, Nicol DL, Clements JA. Characterization of a novel gene, STAG1/PMEPA1, upregulated in renal cell carcinoma and other solid tumors. Mol Carcinog. 2001;32:44–53. [PubMed]
13. Samarnthai N, Saikumar P, Singha P, Venkatachalam MA, Gunn SR, Yeh I. TMEPAI Gene Amplification in Triple Negative Breast Cancers. Mod Pathol. 2010;23:70A.
14. Watanabe Y, Itoh S, Goto T, et al. TMEPAI, a transmembrane TGF-beta-inducible protein, sequesters Smad proteins from active participation in TGF-beta signaling. Mol Cell. 2010;37:123–34. [PubMed]
15. Kar R, Singha PK, Venkatachalam MA, Saikumar P. A novel role for MAP1 LC3 in nonautophagic cytoplasmic vacuolation death of cancer cells. Oncogene. 2009;28:2556–68. [PMC free article] [PubMed]
16. Parish CR, Jakobsen KB, Coombe DR. A basement-membrane permeability assay which correlates with the metastatic potential of tumour cells. Int J Cancer. 1992;52:378–83. [PubMed]
17. Geng H, Lan R, Wang G, et al. Inhibition of autoregulated TGFbeta signaling simultaneously enhances proliferation and differentiation of kidney epithelium and promotes repair following renal ischemia. Am J Pathol. 2009;174:1291–308. [PubMed]
18. Lan R, Geng H, Hwang Y, et al. A novel wounding device suitable for quantitative biochemical analysis of wound healing and regeneration of cultured epithelium. Wound Repair Regen. 2010;18:159–67. [PMC free article] [PubMed]
19. Rhodes DR, Yu J, Shanker K, et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A. 2004;101:9309–14. [PubMed]
20. Farina AR, Coppa A, Tiberio A, et al. Transforming growth factor-beta1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. Int J Cancer. 1998;75:721–30. [PubMed]